Vanguard Group’s Nautilus Biotechnolgy NAUT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$5.07M Buy
2,598,223
+166,394
+7% +$273K ﹤0.01% 3248
2025
Q3
$2.05M Sell
2,431,829
-53,252
-2% -$39.1K ﹤0.01% 3575
2025
Q2
$1.8M Sell
2,485,081
-287,627
-10% -$216K ﹤0.01% 3568
2025
Q1
$2.39M Sell
2,772,708
-5,741
-0.2% -$8.53K ﹤0.01% 3436
2024
Q4
$4.67M Buy
2,778,449
+12,106
+0.4% +$29K ﹤0.01% 3300
2024
Q3
$7.88M Buy
2,766,343
+42,747
+2% +$111K ﹤0.01% 3072
2024
Q2
$6.37M Sell
2,723,596
-135,806
-5% -$355K ﹤0.01% 3143
2024
Q1
$8.41M Buy
2,859,402
+29,604
+1% +$84K ﹤0.01% 3056
2023
Q4
$8.46M Buy
2,829,798
+21,613
+0.8% +$61.8K ﹤0.01% 3045
2023
Q3
$8.87M Buy
2,808,185
+6,279
+0.2% +$20.4K ﹤0.01% 2946
2023
Q2
$10.8M Sell
2,801,906
-38,295
-1% -$110K ﹤0.01% 2899
2023
Q1
$7.87M Buy
2,840,201
+664,825
+31% +$1.39M ﹤0.01% 3070
2022
Q4
$3.92M Sell
2,175,376
-1,313
-0.1% -$2.53K ﹤0.01% 3420
2022
Q3
$4.61M Sell
2,176,689
-3,631
-0.2% -$9.13K ﹤0.01% 3372
2022
Q2
$5.87M Sell
2,180,320
-171,615
-7% -$639K ﹤0.01% 3290
2022
Q1
$10.2M Buy
2,351,935
+1,066,638
+83% +$4.38M ﹤0.01% 3137
2021
Q4
$6.66M Buy
1,285,297
+699,435
+119% +$3.74M ﹤0.01% 3451
2021
Q3
$3.6M Buy
+585,862
New +$4.67M ﹤0.01% 3834

Other funds holding NAUT

Vanguard Group's NAUT Position: Q4 2025 in Review

Vanguard Group increased its Nautilus Biotechnolgy (NAUT) stake by 6.8% in Q4 2025, buying an estimated $273K and bringing the position to 2,598,223 shares worth $5.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3248.

Vanguard Group first reported a position in NAUT in Q3 2021 and has held it in 18 quarters since. The position peaked at $10.8M in Q2 2023. 68 funds tracked by Wall St. Rank hold NAUT as of Q4 2025.

  • Vanguard Group held 2,598,223 shares of Nautilus Biotechnolgy worth $5.07M as of Q4 2025.
  • Vanguard Group bought 166,394 Nautilus Biotechnolgy shares in Q4 2025, an estimated $273K.
  • Nautilus Biotechnolgy made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3248 holding.
  • Vanguard Group first reported a position in Nautilus Biotechnolgy in Q3 2021 and has held it in 18 quarters since.
  • Vanguard Group's Nautilus Biotechnolgy position peaked at $10.8M in Q2 2023.
  • 68 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.